A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial is a Phase 2b/Phase
3 study to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in
patients with Pulmonary Arterial Hypertension (PAH). The Phase 2b part of the study will
assess three doses to establish an optimal dose for the Phase 3 part of the study. The Phase
2b primary endpoint will be the placebo corrected change in pulmonary vascular resistance
(PVR). The Phase 3 primary endpoint will be the placebo corrected change in 6-minute walk
distance (6MWD) after 24 weeks of treatment.